Stifel 2026 Healthcare Conference 2026
Logotype for Kestra Medical Technologies Limited

Kestra Medical Technologies (KMTS) Stifel 2026 Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Kestra Medical Technologies Limited

Stifel 2026 Healthcare Conference 2026 summary

11 Nov, 2026

Market growth and clinical evidence

  • WCD market growth reached 14% on a dollar basis last FY; 850,000 patients are indicated annually, but only one in seven receives a prescription.

  • Post-approval studies covering 21,000 and 19,000 patients highlighted elevated cardiac-arrest risk among non-ischemic cardiomyopathy and heart-failure patients.

  • Broader patient eligibility and category awareness support expectations for durable market growth and an extended opportunity for product adoption.

  • A national payer expanded coverage for non-ischemic cardiomyopathy patients; an HRS expert paper and payer adoption reflect growing influence of clinical evidence.

  • Guideline timing remains uncertain; outcomes data from ACE-PAS patients are being gathered, with information expected in 12–18 months and no large randomized trial expected to be needed.

Innovation and platform plans

  • AI is being applied to patient outreach and device returns, customer-care requests, revenue-cycle tasks and sales planning; AI already handles medical-record reviews.

  • A late-stage capability is expected to be discussed before calendar year-end after reaching the agency-submission milestone; Biobeat blood-pressure monitoring remains in R&D and regulatory work.

  • New capabilities aim to add clinical utility and near-term product differentiation, with longer-term potential for standalone monetization and margin benefit.

  • The five-year ASSURE vision is a wearable platform with expanded monitoring, diagnostic and therapeutic capabilities, alongside technology for adjacent patient populations.

Commercial execution

  • Prescriptions need fulfillment within 24–48 hours; customer-experience priorities include approval, fitting, training and follow-up for both prescribers and patients.

  • About 50 sales territories were added last year, with 30–40 more planned this year in a gradual rollout alongside clinical support and medical education.

  • Revenue growth depends on coordinated sales hiring, education and service delivery to capture market opportunity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kestra Medical Technologies